-
- David F. Schneider
- Assistant Professor of Surgery, Section of Endocrine Surgery, Department of Surgery University of Wisconsin School of Medicine and Public Health Madison WI
-
- Herbert Chen
- Professor of Surgery, Chairman, Division of General Surgery, Vice‐Chairman of Research, Department of Surgery, Layton F. Rikkers, MD, Chair in Surgical Leadership, Section of Endocrine Surgery, Department of Surgery University of Wisconsin School of Medicine and Public Health Madison WI
説明
<jats:p><jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.wileyhealthlearning.com/acs.aspx">Answer questions and earn CME/CNE</jats:ext-link></jats:p><jats:p>Thyroid cancer exists in several forms. Differentiated thyroid cancers include those with papillary and follicular histologies. These tumors exist along a spectrum of differentiation, and their incidence continues to climb. A number of advances in the diagnosis and treatment of differentiated thyroid cancers now exist. These include molecular diagnostics and more advanced strategies for risk stratification. Medullary cancer arises from the parafollicular cells and not the follicular cells. Therefore, diagnosis and treatment differs from those of differentiated thyroid tumors. Genetic testing and newer adjuvant therapies have changed the diagnosis and treatment of medullary thyroid cancer. This review will focus on the epidemiology, diagnosis, workup, and treatment of both differentiated and medullary thyroid cancers, focusing specifically on newer developments in the field. <jats:bold>CA Cancer J Clin 2013;63:373‐394. <jats:sup>©</jats:sup>2013 American Cancer Society, Inc.</jats:bold></jats:p>
収録刊行物
-
- CA: A Cancer Journal for Clinicians
-
CA: A Cancer Journal for Clinicians 63 (6), 373-394, 2013-06-24
Wiley
